Compare Marathon Digital Holdings Inc (MARA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Digital Holdings Inc vs Neurocrine Biosciences Inc — how do they compare? Marathon Digital Holdings Inc trades at $10.15 (market cap $3.83B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.7× Marathon Digital Holdings Inc's market cap, and Marathon Digital Holdings Inc is more actively traded (47,742,698 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Marathon Digital Holdings Inc for 22 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MARA | NBIX | |
|---|---|---|
Market Cap | $3.83B | $14.36B |
Volume | 47,742,698 | 1,237,180 |
Sector | Financials | Health |
52-Week High | $22.84 | $185.50 |
52-Week Low | $6.73 | $123.10 |
Typical Hold Time | 22 Days | 23 Days |
Enterprise Value | $5.87B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MARA stock trades at $10.36, down 5.56% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported significant losses with a net income margin of -429.71% in 2026, though valuation ratios appear attractive with P/E of 3.37 and EV/EBITDA of 3.31. Recent earnings have consistently missed expectations, with Q2 2026 EPS of -1.60 versus expected 0.17.
The outlook remains challenging due to persistent losses and negative cash flow from operations. Analyst consensus is divided with 45% buy ratings and a $13.25 price target, suggesting 28% upside potential. Key risks include execution challenges, competitive pressures, and reliance on financing activities to sustain operations.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
